

strain, and selecting said at least one [or more] peptide[s] of the library able to bind said antibody molecule.

A1 8. (Amended) A method according to claim 7 wherein [the] said at least one peptide [or peptides] selected contain an epitope immunologically cross-reactive with the HVR1 of a plurality of strains of HCV.

9. (Amended) A method according to claim 8 including bringing into contact a library of peptides according to [any of] claim[s] 1 [to 5] and a plurality of antibody molecules collectively able to bind the HVR1 of a plurality of strains of HCV.

A2 11. (Amended) A method according to [any of] claim[s] 7 [to 10] wherein said library is displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the peptide displayed on its surface.

A3 14. (Amended) A method according to [any of] claim[s] 7 [to 13] wherein a peptide with the amino acid sequence of [a] said selected peptide is provided in isolated form.

A4 17. (Amended) A method according to [any of] claim[s] 14 [to 16] wherein said at least one peptide with the amino acid sequence of a said selected peptide [said plurality of peptides or said mixture of plurality of peptides] in isolated form is provided by a process selected from the group consisting of expression from encoding nucleic acid and peptide synthesis.

AS 19. (Amended) A method according to [any of] claim[s] 14 [to 18] wherein said at least one peptide with the amino acid sequence of a said selected peptide[, said plurality of peptides or said mixture of plurality of peptides] in isolated form is formulated into a composition including at least one additional component.

AG 22. (Amended) A method according to [any of] claim[s] 7 [to 17] wherein the amino acid sequence of a said selected peptide is provided in a fusion with additional amino acids.

AG 24. (Amended) A method according to claim 22 [or claim 23] wherein said fusion is formulated into a composition including at least one additional component.

AG 31. (Amended) A method according to [any of] claim[s] 7 [to 30] wherein said at least one selected peptide has [or selected peptides each have] an amino acid sequence according to the following formula ("Formula II"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
T R G L S
R Q P

Subl
AG 32. (Amended) A mixture of 108 different peptides obtainable from a library according to [any of] claim[s] 1 [to 6], wherein each of the 108 different peptides has an amino acid sequence according to the following formula ("Formula II"):

A8
 Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
 T R G L S
 R Q P

Sub D3
 A9
 35. (Amended) A composition according to claim 33 [or claim 34] including [any] at least one [or more] of the peptides G31, F78, R9, D6, M122 and H1 of which the amino acid sequences are shown in Figure 7(A).

A10
 39. (Amended) A composition according to [any of] claim[s] 33 [to 38] wherein [one or more of] said plurality of peptides is in a fusion with additional amino acids.

A11
 42. (Amended) A composition according to [any of] claim[s] 33 to 41] 39 including at least one additional component.

Sub D7
 A72
 46. (Amended) A peptide obtainable from a library according to [any one of] claim[s] 1 [to 5].

Sub A21
 A13
 49. (Amended) A composition including a peptide [according to any of claims 46 to 48] selected from the group consisting of

a) a peptide obtainable from a library as claimed in claim 1; and

2.11 QTHTVGGVQGRQAHSLTSLFSPGASON; and

D6 QTTTTGGOVSHATHGLTGLFSLGPQOK; and

D18 QHTTGGSSASHQASGLTRLFSQGPSON; and

F63 QTHVVGGOQGRQVSSLVSLFSPGASOK; and

G31 THTTVGGSVAROVHSLTGLFSPGPQOK; and

L13 QHTTVGGSQAHAAHSLTRLFSPGSSON; and

M69 QTTVVGGSQARAAHGLVSLFSLGSKON; and

Z61 QTHVVGGOGRQTSGLVGLFSPGSKON; and

R9 OTTVVGGSQSHTVRGLTSLFSPGASON; and
B26 TTTTTGGQAGHQAHSLTSLFSPGASOK; and
B22 OTHVVGGVQSHOTSGLTSLFSPGASOK; and
B35 QHTTTGGVQGHOTSRLTSLFSPGPSON; and
D29 TTTVVGGQAAHOTHSLTSLFSPGAKON; and
D33 TTTTTGGQOSHTVHGLVGLFSPGSKON; and
E26 QHTTVGGVQAHTVRGLTSLFSPGSSON; and
F80 QHTTTGGQAGHTASSLTGLFSPGAKON; and
F19 QTTTVGGVASHQAHSLTGLFSPGAKOK; and
F78 QHTTTGGQAGHQAHSLTGLFSPGAKON; and
H1 QHTTTGGVVGHATSGLTSLFSPGPSOK; and
L76 TTTTVGGQASHOTSSTLTGLFSPGSKON; and
B24 TTTTVGGQASHTTSSLTGLFSPGASOK; and
M63 QHTTTGGVVSHQTRSLVGLFSPGPQON; and
M27 QTTTTGGVASHAAHRLTSLFSPGPQOK; and
M122 QTTTTGGSASHAVSSLTGLFSPGSKON; and
M129 OTTVVGGSAGHTASSLVGLFSPGSKON; and
M119 TTTTVGGQASHTTSSLTGLFSPGSQON; and
R5 QHTTTGGQASHQVSSLVSLFSPGAKOK; and
R6 TTTTTGGQVGHOTSGLTGLFSPGAQON; and
R27 TTHVVGGSASHAVRGLTSLFSPGSSON; and
B14 OTTVTGOASHTTSSLTGLFSPGASOK; and
B33 ATHATGGQAAHSTHSLTSLFSPGASOK; and
F81 QTHVTGGSAAHOTGGLTGLFSPGPKON; and
B18 OTTVVGGQASHVSRLTGLFSPGSSOK; and
E19 THTTGGOQAHTTSRLVSLFSPGASOK; and
L72 OTTTAAHTTSGLTGLFSPGAKON; and
D20 QTHVTGVAGROTSGLVSLFSPGSSON; and
D30 OGGVQGHTTSSLVGLFSPGSQON.

50. (Amended) A composition including a plurality of peptides according to [any of] claim[s] [46 to 48] 49.

AB 51. (Amended) A composition according to claim 50 including 2 to about 10 different peptides [according to any of claims 46 to 48].

52. (Amended) A composition according to [any of] claim[s] [49 to 51] 50 wherein one or more of said peptides is in a fusion with additional amino acids.

A14 55. (Amended) A composition according to [any of] claim[s] 49 [to 54] including at least one additional component.

A15 58. (Amended) ~~Nucleic acid encoding at least one peptide according to [any of] claim[s] 45 [to 48].~~

A16 60. (Amended) ~~Nucleic acid according to claim 58 [or claim 59] operably linked to regulatory sequences for expression of [the] said at least one encoded peptide [or peptides].~~

A17 62. (Amended) A method for production of at least one peptide [or peptides] according to [any of] claim[s] 45 [to 48], the method including causing expression from nucleic acid ~~[according to claim 60]~~ encoding said peptide in a host cell.

A18 64. (Amended) A method according to claim 62 [or claim 63] including isolation and[/or] purification of said at least one peptide [or peptides].

65. (Amended) A method according to [any of] claim[s] [62 to] 64 including formulating said at least one peptide [or peptides] into a composition including at least

11/18
one additional component.

68. (Amended) A method of obtaining at least one [or more] antibody molecule[s] containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including bringing into contact a population of antibody molecules and a peptide according to [any of] claim[s] 45 [to 48], and selecting said at least one [or more] antibody molecule[s] of the population able to bind said peptide.

70. (Amended) A method according to claim 68 [or claim 69] wherein the peptides are provided in a fusion with additional amino acids.

71. (Amended) A method according to [any of] claim[s] [68 to] 70 wherein said at least one peptide [or plurality of peptides] is administered to a non-human mammal to bring it [or them] into contact with a population of antibody molecules produced by the mammal's immune system, [then] followed by isolation of said at least one [or more] antibody molecule[s] able to bind said peptide [or peptides is taken] from the mammal.

72. (Amended) A method according to [any of] claim[s] 68 [to 70] wherein [the] said at least one peptide [or peptides are] is administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system, [then] followed by isolation of cells producing antibody molecules able to bind [the] said at least one peptide [or peptides

are taken] from the mammal.

73. (Amended) A method according to claim 72 wherein said antibody molecule(s) are [taken] isolated from said cells [or descendants thereof] producing said antibody molecules.

74. (Amended) A method according to [any of] claim[s] 71 to 73] 72 wherein the mammal is sacrificed.

75. (Amended) A method according to [any of] claim[s] 68 [to 70] wherein the population of antibody molecules is displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the antibody molecule displayed on its surface.

76. (Amended) A method according to claim 75 wherein nucleic acid is taken from a bacteriophage particle displaying an antibody molecule able to bind said at least one peptide [or peptides].

77. (Amended) A method according to claim 76 including producing an antibody molecule by expression from nucleic acid with the sequence of nucleic acid taken from a bacteriophage particle displaying an antibody molecule able to bind said at least one peptide [or peptides].

78. (Amended) A method according to [any of] claim[s] [68 to] 77 wherein an antibody molecule able to bind said at least one peptide [or peptides] is provided in isolated form.

81. (Amended) A method according to [any of]

claim[s] 78 [to 80] wherein said at least one antibody molecule [, plurality of antibody molecules or mixture of plurality of antibody molecules] in isolated form is provided by expression from encoding nucleic acid.

A21 82. (Amended) A method according to [any of] claim[s] 78 [to 81] wherein said at least one antibody molecule [, plurality of antibody molecules or mixture of plurality of antibody molecules] in isolated form is formulated into a composition including at least one additional component.

84. An antibody molecule obtained by a method according to [any of] claim[s] 68 [to 83].

A22 85. (Amended) A method for raising antibodies in a mammal, said method comprising administering [Use of] a composition according to [any of] claim[s] 33 [to 44] [in the manufacture of a medicament for raising in] to a mammal, thereby stimulating production of antibodies able to bind HCV HVR1 epitopes.

86. (Amended) A method for raising antibodies in a mammal, said method comprising administering [Use of] a peptide according to [any of] claim[s] 45 [to 48] [in the manufacture of a medicament for raising in] to a mammal, thereby stimulating production of antibodies able to bind HCV HVR1 epitopes.

A23 88. (Amended) A method for producing anti-HCV antibodies in a mammal, said method comprising expression of a [Use of] nucleic acid according to [any of] claim[s] 58 [to 60] in the manufacture of a medicament for raising

in a mammal antibodies able to bind HCV HVR1 epitopes.

89. (Amended) A method for increasing antibody levels in a mammal, comprising administering [Use of] an antibody molecule according to claim 84 [in the manufacture of a medicament for increasing in] to a mammal, thereby increasing the level of antibodies able to bind HCV HVR1 epitopes in said mammal.

1723 90. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to [any of] claim[s] 33 [to 44] to the mammal.

91. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a peptide according to [any of] claim[s] 45 [to 48] to the mammal.

92. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to [any of] claim[s] 49 [to 57] to the mammal.

93. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering nucleic acid according to [any of] claim[s] 58 [to 60] to the mammal.

1724 95. (Amended) A method according to [any of] claim[s] 90 [to 94] which is prophylactic.